Novartis Acquires U.S. Cancer Specialist CoStim

Swiss pharmaceuticals giant Novartis has announced plans to acquire U.S. biotech firm CoStim. The privately owned cancer therapy specialist based at Cambridge, Massachusetts, focuses on harnessing the immune system to eliminate immune-blocking signals from cancer.

Financial terms of the deal were not disclosed.

With the acquisition, Novartis said it is adding late discovery stage immunotherapy programs directed to several targets, including PD-1. These medicines, it added, could benefit patients by circumventing cancer's ability to develop resistance against current single drugs.

The Swiss drugmaker already is deeply engaged in cancer immunotherapy, developing investigative chimeric antigen receptor (CAR) technology in collaboration with the University of Pennsylvania.

"Therapy for many types of cancers is expected to increasingly rely upon rational combinations of agents," said Mark Fishman, president of the Novartis Institutes for BioMedical Research. "Immunotherapy agents provide additional arrows in our quiver for such combinations. They complement our extensive portfolio of drugs that hit genetically-defined cancer-causing pathways, and also may be relevant to expansion of CAR therapies," he said. 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.